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Abstract
BACKGROUND
Idiopathic non-cirrhotic portal hypertension (INCPH) is mainly associated with
thrombophilia in Western countries. Paroxysmal nocturnal hemoglobinuria
(PNH) is a rare hematologic disease that manifests with hemolytic anemia,
thrombosis, and peripheral blood cytopenias. Portal and hepatic venous
thrombosis were reported in PNH. A rare case of INCPH complicating PNH is
described.
CASE SUMMARY
A 63-year old woman with a 2-year past medical history of PNH without
treatment was admitted because of jaundice and refractory ascites requiring large
volume paracentesis. Liver histology revealed portal venopathy with portal
fibrosis and sclerosis, nodular regenerative hyperplasia, parenchymal ischemic
changes, and focal sinusoidal and perivenular fibrosis without bridging fibrosis
or cirrhosis, all indicative of INCPH. The flow cytometry confirmed PNH
diagnosis and eculizumab treatment was initiated. Her condition was improved
gradually, bilirubin was normalized 6 months following initiation of eculizumab,
and 1 year later diuretics were stopped.
CONCLUSION
Eculizumab improved intravascular hemolysis and reversed clinical
manifestations of INCPH in a patient with paroxysmal nocturnal
hemoglobinuria.
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Core tip Idiopathic non-cirrhotic portal hypertension diagnosis is based on liver
histology, the clinical signs of portal hypertension, and the exclusion of chronic liver
diseases in the absence of portal and hepatic venous thrombosis. We describe a patient
with paroxysmal nocturnal hemoglobinuria who presented with intravascular hemolysis,
jaundice, and refractory ascites. Abdominal portosystemic collaterals were evident in
imaging without varices in endoscopy. Liver histology demonstrated portal venopathy,
features of nodular regenerative hyperplasia, and ischemic parenchymal changes without
cirrhosis, all indicative of idiopathic non-cirrhotic portal hypertension. Eculizumab
treatment achieved improvement of hemolysis and reversion of biochemical and clinical
manifestations of liver disease.
Citation: Alexopoulou A, Mani I, Tiniakos DG, Kontopidou F, Tsironi I, Noutsou M,
Pantelidaki H, Dourakis SP. Successful treatment of noncirrhotic portal hypertension with
eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. World J Hepatol 2019;
11(5): 483-488
URL: https://www.wjgnet.com/1948-5182/full/v11/i5/483.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i5.483
INTRODUCTION
Idiopathic non-cirrhotic portal hypertension (INCPH) is evidenced by the presence of
an increased portal venous pressure gradient despite the absence of a known cause of
chronic liver disease and portal vein thrombosis[1]. In India, INCPH accounts for 23%
of portal  hypertension cases[2],  while  in the Western world,  it  is  very rare[3].  The
etiology is  heterogeneous and varies according to the geographical  area and the
population  studied[4,5].  INCPH is  often  misdiagnosed  as  liver  cirrhosis,  so  liver
histology is required to differentiate between the two entities[1]. Histological features
in liver specimens from patients with INCPH include obliterative portal venopathy,
hepatoportal  sclerosis,  nodular  regenerative  hyperplasia,  and incomplete  septal
cirrhosis[1]. It has been suggested that obliterative portal venopathy may represent an
early stage while nodular regenerative hyperplasia is a late stage of the same disease
currently termed porto-sinusoidal vascular disease[6], which may lead to INCPH[7].
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease[8]  and has not been
reported so far as a cause of INCPH. We herein describe a case of PNH complicated
by INCPH, which was reversed clinically by the administration of eculizumab.
CASE PRESENTATION
Chief complaints
A 63-year old female patient was admitted to the hospital for fatigue, jaundice, and
large-volume ascites.
History of present illness
PNH was diagnosed 2 years earlier when she was admitted for anemia, but she was
lost to follow-up. Six weeks before current admission, portal vein thrombosis was
diagnosed and enoxaparin 60 IU twice daily was initiated.
Physical examination
The abdomen was distended, and the liver was enlarged 4 cm below the right costal
margin. The spleen was mildly enlarged.
Laboratory workup
Blood analysis revealed hemoglobin of 10.8 g/dL, white blood cell count 5.4 × 109/L,
platelets 171 × 109/L, reticulocytes 6.5%, international normalized ratio 1.0,  total
bilirubin 4  mg/dL,  direct  bilirubin 2.6  mg/dL,  aspartate  transaminase  28  IU/L,
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alanine  transaminase  12  IU/L,  alkaline  phosphatase  456  IU/L,  glutamyl
transpeptidase  248  IU/L,  total  protein  6.6  g/dL,  albumin  3.3  g/dL,  lactate
dehydrogenase (LDH) 650 U/L, serum haptoglobin < 7 mg/dL, creatinine 1.7 mg/dL,
urea 81 mg/dL. Ascitic fluid had a serum-ascites albumin gradient of 1.7 g/dL (ascitic
fluid  total  protein  3  g/dL,  albumin  1.6  g/dL).  Hepatitis  B  and  C  and  human
immunodeficiency virus serology was negative. Direct globulin test was negative.
Further work-up
In Doppler ultrasonography of splenoportal axis, recanalization of the portal vein and
large abdominal portosystemic anastomoses were evident. Hepatic veins were patent.
Magnetic  resonance  imaging  showed  hepatomegaly  and  confirmed  the  above
findings. No esophageal or gastric varices were demonstrated in endoscopy. Ascites
was refractory to diuretics and multiple large volume paracenteses were required.
Due to the absence of a clear etiology of portal  hypertension,  a liver biopsy was
performed.
Liver histology
Changes of portal venopathy with portal fibrosis and sclerosis and features of nodular
regenerative hyperplasia were demonstrated. A spectrum of portal vein lesions was
seen in interlobular portal tracts included in the biopsy, ranging from portal venule
herniation in the periportal  parenchyma, to slit-like stenosed portal  venules and
sclerosed portal  tracts  without a visible portal  venule.  In addition,  parenchymal
ischemic changes indicative of decreased venous outflow, mild focal sinusoidal and
perivenular fibrosis, mild cholestasis, and mild secondary siderosis were noted. There
was no bridging fibrosis or cirrhosis (Figure 1). The overall changes supported the
diagnosis of INCPH.
Hematology work-up
The flow cytometry at this point revealed that 16.5% of her red blood cells were PNH,
4.1% were partially deficient for CD59, and 12.4% lacked CD59 completely; 63% of her
granulocytes and 60% of monocytes were PNH.
FINAL DIAGNOSIS
INCPH complicating PNH was diagnosed.
COURSE OF THE DISEASE
Paroxysms of abdominal pain, debilitating fatigue, dyspnea, deepening of jaundice
(total bilirubin 21 mg/dL, direct bilirubin 14.4 mg/dL), worsening of renal function
(creatinine 2.2 mg/dL), anemia (Hb 7.6 g/dL), and thrombocytopenia (80 × 109/L)
developed over the next 8 weeks, and the patient became bedridden. Vaccination for
Neisseria  meningitis  was  performed  as  a  prophylaxis  for  future  therapy  with
eculizumab.
TREATMENT
Eculizumab was initiated at a regular dosing for patients with PNH (600 mg weekly
for the first 5 weeks followed by 900 mg biweekly thereafter).
OUTCOME AND FOLLOW-UP
Three months following eculizumab initiation, no more therapeutic paracentesis of
ascitic fluid was required and diuretics were administered. Serum bilirubin, LDH,
hemoglobin, and reticulocyte count improved gradually (Figure 2). Renal function,
serum bilirubin,  LDH, and platelets normalized 6 months following initiation of
eculizumab. One year later,  diuretics  were stopped without reappearance of  the
ascites. No direct antiglobulin test was evident during follow-up. Anticoagulation
treatment with enoxaparin was continued during hospitalization and follow-up.
DISCUSSION
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Figure 1
Figure 1  Selected images from the liver biopsy showing changes of portal venopathy and features of nodular regenerative hyperplasia. A: A sclerosed PT
without a visible portal vein. Peripherally, a dilated portal vein radicle herniates into the adjacent hepatic parenchyma (HE, x 10); B: Nodular regenerative hyperplasia.
White dotted line circumscribes a nodule of regenerating hepatocytes surrounded by atrophic hepatocyte trabeculae (arrow), reticulin stain, x 10; C: THV with
perivenular sclerosis. Sinusoidal dilatation in zone 3 (arrow), (HE, x 10); D: Sinusoidal capillarization in ischemic areas highlighted by CD34 immunostain. Arrow points
to a THV (brown CD 34-positive sinusoidal staining), x 10; E: Keratin 7-positive atrophic hepatocytes indicative of ischemia in zone 3 (brown staining), x 10; F:
Sinusoidal zone 3 fibrosis in zone 3 (arrow) and perivenular fibrosis in midleft, Masson trichrome stain, x 10; G: A fibrosed portal tract with a slit-like portal venule
(arrow), PAS stain, x 20. PT: Portal tract; THV: Terminal hepatic vein; HE: Hematoxylin & eosin.
Our patient fulfilled all the criteria for the diagnosis of INCPH, including the clinical
signs of portal hypertension (ascites and portovenous collaterals in our case), the
exclusion of  cirrhosis  on histology,  the absence of  chronic liver diseases causing
cirrhosis or other conditions causing INCPH, and the patency of portal and hepatic
veins[1].  Although  called  idiopathic,  INCPH  has  been  associated  with  various
conditions, including thrombophilia[9], hematological malignancies[10], infections[11],
medication  and  toxins[12],  genetic[13]  and  immunological  disorders[14].  The  main
symptoms  of  patients  with  INCPH  are  upper  gastrointestinal  bleeding  and
splenomegaly[2,15].  Ascites, as in the current case, was present in 50% of cases in a
French[16] and in 26% in a Spanish study[17]. Prothrombotic disorders accounted for
48% in the former and 8% in the latter. Our case demonstrated the presence of large
abdominal portosystemic collaterals. However, esophageal or gastric varices were not
evident, probably due to the early stage of portal hypertension. Chronic ascites may
be attributed both to portal hypertension and the concomitant renal failure in keeping
with published literature[1]. Kidney disease is a common manifestation of PNH and is
a  result  of  tubular  damage  caused  by  microvascular  thrombosis  and  renal  iron
accumulation[8].
From a pathophysiology point of view, in thrombophilia cases of INCPH, increased
intrahepatic resistance ensuing from obliteration of the portal venous microcirculation
may result in an increase in portal blood pressure[7,18]. High levels of endothelin-1
might  further  increase  vascular  resistance  and  stimulate  periportal  collagen
production[19].  Another  hypothesis  is  that  the prothrombotic  disorder  affects  the
sinusoidal  and  portal  vein  wall  causing  fibrosis,  obstruction,  and  secondary
alterations in hepatic architecture[10]. In the case of PNH, the accumulation of high
levels of free hemoglobin, which is a potent nitric oxide scavenger[20], may play a role
in increasing vascular resistance. Nitric oxide maintains smooth muscle relaxation and
inhibits platelet activation and aggregation[21]. Its deficiency may contribute to smooth
muscle tone increase and platelet activation.
In PNH, deficiency of the glycosyl phosphatidylinositol-anchored complement
regulatory proteins CD55 and CD59 induces the intravascular hemolysis that is the
main clinical manifestation of the disease[22,23]. Thrombotic events occur in about 27%
of  patients  with  PNH  and  are  the  main  cause  of  mortality,  accounting  for
approximately 40% of deaths[24]. Hepatic and portal veins are considered common
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Figure 2
Figure 2  Clinical and laboratory course of the disease before and after treatment with eculizumab.
sites of thrombosis[25]. Eculizumab is a monoclonal blocking antibody to complement
protein  C5,  which  inhibits  cleavage  to  C5a  and  C5b  and  impedes  terminal
complement complex C5b-9[26]. Trials with eculizumab demonstrated a reduction in
hemolysis,  stabilization  of  hemoglobin  levels,  and  a  reduction  in  transfusion
requirements but also a protection against the complications of hemolytic PNH, such
as deteriorating renal function, pulmonary hypertension, and thromboembolism[27].
The patient presented has a large clone (> 50% PNH granulocytes and > 10% PNH
red cells)  combined with  a  notably  increased LDH as  evidence  of  intravascular
hemolysis and a high reticulocyte count. In addition, platelet count was normal and
anemia was mild without transfusion requirement,  indicating an adequate bone
marrow reserve. Thus, she had many chances to benefit from eculizumab treatment as
the drug is highly effective in abrogating the intravascular hemolysis of PNH and
reducing  the  risk  of  thrombosis  but  does  not  alleviate  bone  marrow  failure  if
present[28].  Eculizumab is  expensive and should be administered indefinitely for
achieving sustained response. It has been stated that the drug has changed the natural
course of PNH[29].
In  our  case,  long-term  treatment  with  eculizumab  in  combination  with
anticoagulation in a patient with PNH and INCPH resulted in improvement of the
symptoms of liver disease, elimination of intravascular hemolysis, gradual resolution
of kidney disease, and improvement of quality of life. The beneficial effect of the drug
on liver microcirculation may be a result of the elimination of the prothrombotic
disorder and the decrease of vascular resistance of the sinusoidal and portal venous
walls.
CONCLUSION
Long-term administration of the monoclonal antibody eculizumab controlled the
symptoms and life-threatening complications of PNH. More specifically, it reversed
the complications of INCPH, as indicated by the elimination of large ascites and
jaundice and normalization of liver function tests.  Furthermore,  it  abrogated the
intravascular hemolysis and improved dramatically the quality of life.
REFERENCES
1 Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension.
Hepatology 2011; 54: 1071-1081 [PMID: 21574171 DOI: 10.1002/hep.24422]
2 Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Lesmana LA, Guha Mazumder D,
Omata M, Qureshi H, Raza RM, Sahni P, Sakhuja P, Salih M, Santra A, Sharma BC, Sharma P, Shiha G,
Sollano J; Members of the APASL Working Party on Portal Hypertension. Noncirrhotic portal
fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int
2007; 1: 398-413 [PMID: 19669336 DOI: 10.1007/s12072-007-9010-9]
3 Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64
cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990;
11: 787-797 [PMID: 2189821 DOI: 10.1002/hep.1840110512]
4 Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S. Chronic arsenic toxicity in west
Bengal--the worst calamity in the world. J Indian Med Assoc 1998; 96: 4-7, 18 [PMID: 9601181]
WJH https://www.wjgnet.com May 27, 2019 Volume 11 Issue 5
Alexopoulou A et al. Non-cirrhotic portal hypertension complicating paroxysmal nocturnal hemoglobinuria
487
5 Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, Soriano V. Noncirrhotic portal
hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-
1176 [PMID: 20299955 DOI: 10.1097/QAD.0b013e3283389e26]
6 De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad SD, Vilgrain V,
Hernandez-Gea V, Nery F, Plessier A, Berzigotti A, Bioulac-Sage P, Primignani M, Semela D, Elkrief L,
Bedossa P, Valla D, Garcia-Pagan JC; VALDIG group. Porto-sinusoidal vascular disease: proposal and
description of a novel entity. Lancet Gastroenterol Hepatol 2019; 4: 399-411 [PMID: 30957754 DOI:
10.1016/S2468-1253(19)30047-0]
7 Elkrief L, Rautou PE. Idiopathic non-cirrhotic portal hypertension: the tip of the obliterative portal
venopathies iceberg? Liver Int 2016; 36: 325-327 [PMID: 26872111 DOI: 10.1111/liv.13048]
8 Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood 2014; 124: 2804-2811 [PMID: 25237200
DOI: 10.1182/blood-2014-02-522128]
9 Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol
Int 2018; 12: 148-167 [PMID: 29464506 DOI: 10.1007/s12072-018-9844-3]
10 Schouten JN, Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare
Dis 2015; 10: 67 [PMID: 26025214 DOI: 10.1186/s13023-015-0288-8]
11 Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, Galambos MR, Rubin RA. Noncirrhotic
portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol
Hepatol 2008; 6: 1167-1169 [PMID: 18639498 DOI: 10.1016/j.cgh.2008.04.023]
12 Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L, Barreiro P, Mura MS,
Babudieri S, Albertos S, Garcia-Samaniego J, Soriano V. Antiretroviral-associated portal hypertension: a
new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13: 103-107 [PMID:
18389904]
13 Roulot D, Degott C, Chazouillères O, Oberti F, Calès P, Carbonell N, Benferhat S, Bresson-Hadni S,
Valla D. Vascular involvement of the liver in Turner's syndrome. Hepatology 2004; 39: 239-247 [PMID:
14752843 DOI: 10.1002/hep.20026]
14 Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease:
potential role of IgA anticardiolipin antibody. Gut 2004; 53: 1032-1034 [PMID: 15194657 DOI:
10.1136/gut.2003.036806]
15 Okuda K, Kono K, Ohnishi K, Kimura K, Omata M, Koen H, Nakajima Y, Musha H, Hirashima T,
Takashi M. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with
cirrhosis with splenomegaly. Gastroenterology 1984; 86: 600-610 [PMID: 6698361]
16 Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, Valla D, Degott C. Idiopathic
non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:
275-280 [PMID: 12117894 DOI: 10.1136/gut.51.2.275]
17 Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, Turon F, Hernandez-Gea
V, Bosch J, Garcia-Pagán JC. Idiopathic portal hypertension: natural history and long-term outcome.
Hepatology 2014; 59: 2276-2285 [PMID: 24155091 DOI: 10.1002/hep.26904]
18 Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, Francoz C, Denninger MH,
Durand F, Bedossa P, Valla DC. Obliterative portal venopathy: portal hypertension is not always present at
diagnosis. J Hepatol 2011; 54: 455-461 [PMID: 21087805 DOI: 10.1016/j.jhep.2010.07.038]
19 Kamath PS, Carpenter HA, Lloyd RV, McKusick MA, Steers JL, Nagorney DM, Miller VM. Hepatic
localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver
Transpl 2000; 6: 596-602 [PMID: 10980059 DOI: 10.1053/jlts.2000.9735]
20 Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and
extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293: 1653-1662
[PMID: 15811985 DOI: 10.1001/jama.293.13.1653]
21 Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 1989; 3: 31-36 [PMID:
2642868 DOI: 10.1096/fasebj.3.1.2642868]
22 Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T, Kinoshita T. Abnormalities of PIG-A
transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994;
330: 249-255 [PMID: 8272086 DOI: 10.1056/nejm199401273300404]
23 Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T. Paroxysmal
nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13:
110-117 [PMID: 8306954 DOI: 10.1002/j.1460-2075.1994.tb06240.x]
24 Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Pathophysiology, diagnosis, and treatment of
paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol 2015; 95: 190-198 [PMID: 25753400
DOI: 10.1111/ejh.12543]
25 Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal
hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 2007; 5: 642-645 [PMID:
17319910 DOI: 10.1111/j.1538-7836.2007.02379.x]
26 Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO,
Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA,
Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal
hemoglobinuria. N Engl J Med 2006; 355: 1233-1243 [PMID: 16990386 DOI: 10.1056/NEJMoa061648]
27 Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de
Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study
of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal
hemoglobinuria. Blood 2008; 111: 1840-1847 [PMID: 18055865 DOI: 10.1182/blood-2007-06-094136]
28 Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory
WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained
efficacy and improved survival. Blood 2011; 117: 6786-6792 [PMID: 21460245 DOI:
10.1182/blood-2011-02-333997]
29 Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski
JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Long-term safety and efficacy of
sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol
2013; 162: 62-73 [PMID: 23617322 DOI: 10.1111/bjh.12347]
WJH https://www.wjgnet.com May 27, 2019 Volume 11 Issue 5
Alexopoulou A et al. Non-cirrhotic portal hypertension complicating paroxysmal nocturnal hemoglobinuria
488
Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com
© 2019 Baishideng Publishing Group Inc. All rights reserved.
